Immunotherapy’s impact is increasing
As soon as a year from now, look for a “completely different paradigm” in the care of squamous non-small cell lung cancer, says Cleveland Clinic medical oncologist James Stevenson, MD. Dr. Stevenson discussed his outlook in detail at the recent 2016 OncLive State of the Science Summit on Metastatic Non–Small Cell Lung Cancer.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
What changes to expect? Immunotherapy moves to the frontline while chemotherapy shifts to a second-line treatment. Read the entire Q&A with Dr. Stevenson.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust